Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€26.52

€26.52

0.490%
0.13
0.490%
€34.34
 
12.07.24 / Tradegate WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Pfizer Inc. Stock

The Pfizer Inc. stock is trending slightly upwards today, with an increase of €0.13 (0.490%) compared to yesterday's price.
With 50 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 34 € there is a positive potential of 28.23% for Pfizer Inc. compared to the current price of 26.52 €.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 14 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.

Pros and Cons of Pfizer Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pfizer Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pfizer Inc. 0.490% 2.493% 3.594% -18.037% 1.590% -20.933% -25.276%
Johnson & Johnson -0.230% 1.747% 2.200% -3.183% -2.910% -3.820% 15.220%
Elanco Animal Health Inc. -0.240% -3.536% -23.480% 36.401% -6.376% -57.150% -
Biogen Inc. -3.400% 1.345% -1.078% -15.397% -10.517% -28.341% 2.927%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.

*Pros: *

Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.

Comments

Prediction Buy
Perf. (%) -0.09%
Target price 30.750
Change
Ends at 12.07.25

Pfizer's stock is currently trading at a reasonable price of $26.54, making it an attractive investment opportunity. The company has been making waves in the pharmaceutical industry, with several promising developments in its pipeline. The recent positive results from the Danuglipron weight-loss drug trial have sparked investor interest, suggesting Pfizer may be able to catch up in the lucrative weight-loss drug race. Additionally, Pfizer's strong financial performance and diversified product portfolio make it a solid choice for long-term investors looking to capitalize on the growth of the healthcare sector. While some analysts have expressed concerns about Pfizer's position relative to competitors, the overall sentiment seems to be that the stock is poised for growth. As an investor, I'm intrigued by Pfizer's potential and believe it could be a smart addition to a well-diversified portfolio.
Show more

Prediction Buy
Perf. (%) 0.04%
Target price 30.000
Change
Ends at 12.07.25

Pfizer, the pharmaceutical giant, has been making waves in the industry with its latest developments. The company's recent trial results for its weight-loss drug, Danuglipron, have generated a lot of buzz, with analysts praising the drug's potential. While Pfizer may be lagging behind in the weight-loss drug race, this trial could be a game-changer. Additionally, the company's strong financial performance and promising pipeline of drugs make it an attractive investment opportunity. As an investor, I'm excited to see what Pfizer has in store for the future. With a solid track record and a focus on innovation, Pfizer seems poised to deliver solid returns for shareholders. Of course, there are always risks involved, but the potential upside seems to outweigh the downside. Why not jump on board and see where this pharmaceutical powerhouse takes us next?
Show more

Prediction Buy
Perf. (%) 0.09%
Target price 29.500
Change
Ends at 12.07.25

Pfizer, the pharmaceutical giant, has been making waves with its recent developments, and the news seems quite promising. The company's experimental weight loss drug, Danuglipron, has shown encouraging results in clinical trials, suggesting it could be a game-changer in the highly competitive weight loss market. While some analysts believe Pfizer is lagging behind in the race, the potential success of this drug could propel the company forward and deliver significant returns for investors. Additionally, Pfizer's strong pipeline of products, including its COVID-19 vaccine, continues to drive revenue growth and solidify its position as a leader in the industry. Given these positive developments, I believe Pfizer is a strong candidate for investment, with the potential to deliver steady growth and attractive returns in the long run. Of course, as with any investment, it's essential to do your own due diligence and consider your personal risk tolerance and investment goals. But based on the information available, Pfizer appears to be a solid pick for those seeking exposure to the pharmaceutical sector.
Show more

News

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipronhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron


Pfizer Inc. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation

Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Developmenthttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development


Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and President, Pfizer Research &amp

Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock: https://g.foolcdn.com/editorial/images/782654/dividend-sign.jpg
Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock

Pfizer (NYSE: PFE) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has